RE: Licence For Production Imminent31 Jul 2019 12:53
In case you all miss this from the CEO last Rns
Letter from the CEO:
28/06/2019 7:00am
UK Regulatory (RNS & others)
With the successful conclusion of last year's acquisition of IVIX LLC ("IVIX") and the re-admission of the enlarged group on Euronext Dublin and the London Stock Exchange, the foundation was put in place for establishing Ovoca as a recognized developer of novel therapeutics for women's health, especially in the area of sexual dysfunction. Our colleagues at IVIX continue to build out our successful BP101 program, which you will have seen in March 2019 comfortably exceeded the efficacy and safety hurdles in its Phase 3 trial in Russia. As a result, we are now preparing to file for the drug's marketing approval in its first country, the Russian Federation, and actively pursuing discussions with potential licensing partners to commercialize there.